NCT02489903 2025-03-17RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)EpicentRx, Inc.Phase 2 Completed139 enrolled 14 charts
NCT02762981 2022-12-06Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid TumorsCorcept TherapeuticsPhase 1/2 Completed85 enrolled 24 charts